MedTrace Logo

Efficacy Study of Betahistine on Body Weight in Obese Female Subjects

NCT00748436 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2009-05-07

No results posted yet for this study

Summary

The purpose of this study is to examine the effect of betahistine on body weight in obese female subjects

Conditions

Interventions

DRUG

betahistine dihydrochloride

(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks

DRUG

betahistine dihydrochloride

(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks

DRUG

placebo

(placebo tablet + placebo tablet) BID per os 12 weeks

Sponsors & Collaborators

  • International Antiviral Therapy Evaluation Center

    collaborator OTHER

  • OBEcure Ltd.

    lead INDUSTRY

Principal Investigators

  • Yaffa Beck, PhD, CEO · OBEcure Ltd.

  • Luc Van Gaal, MD Professor · UZ Antwerpen

  • Nir Barak, MD · OBEcure Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Belgium
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00748436 on ClinicalTrials.gov